Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BGB-23339 in Healthy Japanese and Caucasian Subjects
NCT05387668Phase 1Withdrawn
- Sponsor
- BeiGene
- Start
- Feb 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bgb-23339 in psoriasis and inflammatory bowel disease (IBD), sponsored by BeiGene. Primary endpoint: Adverse Events up to 11 weeks. Planned start Feb 2022; status: withdrawn.
02
Drugs
bgb-23339
03
Conditions
psoriasisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT05387668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387668.